Pharma News
Abbott to buy Russian generics firm
US-based pharma company Abbott Laboratories (Abbott) announced on 23 June 2014 that it had signed a definitive agreement to acquire Russian generics maker Veropharm.
Pfenex looking for funding for its biosimilars pipeline
US biotechnology firm Pfenex is looking to raise more than US$45 million to further its biosimilars pipeline.
Views on biosimilars at Amgen and Actavis
Biotech giant Amgen and US generics maker Actavis entered into a collaboration for the development and commercialization of several cancer antibody biosimilars back in December 2011 [1]. Now the two companies have spoken to GaBI about their views on biosimilars and their biosimilar plans [2].
Top 10 most read GaBI Online articles in 2013
2013 was a busy year with lots of developments in the biosimilars arena, ranging from revision of regulatory guidelines to new biosimilar approvals. Biosimilars remain the hot topic of the year for GaBI Online during 2013 and in fact all 10 of the most read articles concern biosimilars.
Abbott expands generics business in Latin America
US-based pharma company Abbott Laboratories (Abbott) announced on 16 May 2014 that it was expanding its presence in Latin American and increasing its branded generics portfolio with the acquisition of CFR Pharmaceuticals (CFR).
Pamplona investment group buys majority share in Alvolgen
Specialist investment manager Pamplona Capital Management (Pamplona) announced on 2 April 2014 that it had acquired a majority stake in US generics company Alvogen, one of the fastest growing generics companies in the pharmaceutical industry.
Actavis to acquire generics from Akorn
US generics major Actavis announced on 17 April 2014 that it had made a deal with Akorn and Hi-Tech Pharmacal (Hi-Tech) to buy five of their products.
UK court invalidates Herceptin patents
A High Court in the UK has overturned two key patents on Roche’s breast cancer blockbuster Herceptin (trastuzumab).
Sun Pharma to acquire Ranbaxy creating 5th largest generics firm
India-based Sun Pharmaceutical (Sun Pharma) announced on 6 April 2014 that the company had agreed to acquire rival generics maker Ranbaxy Laboratories (Ranbaxy) in an all-stock deal worth US$3.2 billion.
Actavis buys Thai generics company
US generics major Actavis has acquired Silom Medical Company, a privately held generics firm focused on developing and marketing therapies in Thailand, for around US$100 million in cash.
